In This Article:
The United States market remained flat over the last week but has risen 8.1% in the past 12 months, with earnings expected to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability within a stable economic backdrop.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
| Alkami Technology | 20.45% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.82% | 58.64% | ★★★★★★ |
| AVITA Medical | 27.75% | 55.36% | ★★★★★★ |
| Applied Optoelectronics | 58.93% | 141.15% | ★★★★★★ |
| TKO Group Holdings | 22.54% | 25.17% | ★★★★★★ |
| Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
| Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Cellebrite DI
Simply Wall St Growth Rating: ★★★★★☆
Overview: Cellebrite DI Ltd. provides solutions for legally sanctioned investigations across various regions including Europe, the Middle East, Africa, the Americas, and Asia-Pacific, with a market cap of $4.07 billion.
Operations: Cellebrite DI Ltd. generates revenue primarily from its Internet Software & Services segment, amounting to $401.20 million.
Cellebrite DI, amidst a transformative phase, reported a significant rebound with fourth-quarter revenues soaring to $109.05 million from $93.01 million the previous year and flipping a net loss into a profit of $19.27 million. This turnaround is underscored by an aggressive R&D strategy that not only fuels innovation but also aligns with industry shifts towards more secure and efficient digital forensics solutions. The appointment of tech veteran Michael D. Capellas to the board promises enhanced governance, potentially steering Cellebrite towards sustained growth, especially with projected annual revenue growth at 15.3%, outpacing the US market's 8.5%. This trajectory suggests robust future prospects, albeit in the challenging landscape of high-tech investment where rapid evolution and competition are constants.
-
Navigate through the intricacies of Cellebrite DI with our comprehensive health report here.
-
Gain insights into Cellebrite DI's historical performance by reviewing our past performance report.
Lumentum Holdings
Simply Wall St Growth Rating: ★★★★★★
Overview: Lumentum Holdings Inc. is a company that manufactures and sells optical and photonic products across various regions including the Americas, Asia-Pacific, Europe, the Middle East, and Africa with a market capitalization of $4.72 billion.